On 24 July 2026 the European Medicines Agency (EMA) reported that its Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a marketing authorisation in the European Union for Susvimo (ranibizumab). Susvimo is an intravitreal therapy delivered via a surgically implanted, refillable ocular implant and represents the first implant of this kind recommended for approval in the EU.
Susvimo is proposed for use in adults with neovascular (wet) age-related macular degeneration (nAMD). The intended population is patients whose disease is stable after they have responded to intravitreal treatment with a vascular endothelial growth factor (VEGF) inhibitor medicine. The recommendation specifies use only in combination with the refillable ocular implant that is surgically inserted into the eye.
nAMD is described in the EMA communication as an advanced form of age-related macular degeneration that, if untreated, can cause rapid and severe central vision loss. AMD overall is a chronic, progressive macular disease and a leading cause of central vision impairment among people aged over 50 years.
Susvimo’s delivery system is a surgically inserted, refillable implant designed to release ranibizumab over time. According to the EMA announcement, the implant is refilled every six months. This contrasts with standard care using ranibizumab-containing medicines that are administered by intravitreal injection, typically every four weeks.
The implant-based delivery aims to provide an alternative to frequent intravitreal injections and to reduce the treatment and visit burden associated with monthly injections. The EMA noted that frequent injections and specialist visits can be onerous for patients and carers, may affect treatment adherence, and could contribute to real-world outcomes that differ from results observed in clinical trials.
EMA’s statement summarised pivotal clinical evidence from a phase 3, randomised, visual assessor-masked, active-comparator study that enrolled 415 patients with nAMD. In that trial, Susvimo delivered via the ocular implant was compared with intravitreal ranibizumab injections administered every four weeks.
The study demonstrated that Susvimo was comparable to monthly intravitreal ranibizumab injections in maintaining both visual and anatomical outcomes in patients with nAMD. The EMA communication presents these findings as support for Susvimo as a new treatment option for patients with stable disease following response to conventional intravitreal VEGF inhibitor therapy.
The EMA notice listed the most commonly reported side effects with Susvimo. These included iritis (inflammation of the iris), conjunctival bleb or filtering bleb leak (a small bulge in the conjunctiva, with or without fluid leakage), cataract, vitreous floaters, conjunctival haemorrhage, conjunctival hyperaemia, eye pain and headache.
These adverse reactions reflect safety observations associated with the implant's presence and the surgical procedure as well as local ocular effects. The EMA release provides these events as the most frequently reported; further details, such as incidence rates or severity grading, were not reported in the summary news item and would be found in the full assessment documents or the product information.
The CHMP opinion is an intermediary regulatory milestone. As described by EMA, the CHMP’s positive opinion will be forwarded to the European Commission, which will adopt a decision on an EU-wide marketing authorisation. If the European Commission grants marketing authorisation, that would permit Susvimo to be placed on the market across the EU under the terms of the centralised procedure.
Following any marketing authorisation, decisions on pricing and reimbursement are responsibilities of individual Member States. The EMA communication notes that national authorities will consider the role and use of Susvimo within their respective health systems when making those decisions.
EMA positioned Susvimo as a new treatment option that may ease the treatment burden for patients with stable nAMD, their carers and healthcare systems by reducing the frequency of intravitreal injections and specialist visits. The refill interval for the implant—every six months—was highlighted as a potential advantage compared with the current typical injection interval of every four weeks for ranibizumab therapies.
The agency also noted that frequent injections and regular monitoring can affect patient compliance and therefore visual outcomes in routine practice; an implant-based delivery may address some of these practical barriers for a subset of patients whose disease is stable after initial response.
The EMA news item identifies the applicant for Susvimo as Roche Registration GmbH. The CHMP opinion will be sent to the European Commission as the next regulatory step. The EMA release also included contact details for media enquiries and referred readers to related medicine information on the EMA website, including the Susvimo product page and the committee meeting highlights from 20–23 July 2026.
Note: This summary is based solely on the EMA news release dated 24 July 2026. Details such as full trial data, incidence rates for adverse reactions, and the European Commission decision outcome were not reported in the source and should be consulted in EMA’s full assessment or product documentation when available.